Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2?

Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL (2003) Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 20:749–756

Sakaeda T, Takara K, Kakumoto M, Ohmoto N, Nakamura T, Iwaki K, Tanigawara Y, Okumura K (2002) Simvastatin and lovastatin, but not pravastatin, interact with MDR1. J Pharm Pharmacol 54:419–423

Yamamoto E, Yamashita T, Tanaka T, Kataoka K, Tokutomi Y, Lai ZF, Dong YF, Matsuba S, Ogawa H, Kim-Mitsuyama S (2007) Pravastatin enhances beneficial effects of olmesartan on vascular injury of salt-sensitive hypertensive rats, via pleiotropic effects. Arterioscler Thromb Vasc Biol 27:556–563

Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M (2007) Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 27:631–639

Kobayashi D, Nozawa T, Iwaki K, Nezu J, Tsuji A, Tamai I (2003) Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306:703–708

Shitara Y, Itoh T, Sato H, AP LI, Sugiyama Y (2003) Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610–616

Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U (1999) Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 27:173–179

Holtzman CW, Wiggins BS, Spinler SA (2006) Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 26:1601–1607

Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker DR (1996) CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344–349

Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K (2006) Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol 72:1042–1050

Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y (2005) Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 314:1059–1067

Akashi M, Tanaka A, Takikaw H (2006) Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatol Res 34:193–198

Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164–170

Seithel A, Karlsson J, Hilgendorf C, Bjorquist A, Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291–299

Fujita T, Yamada H, Fukuzumi M, Nishimaki A, Yamamoto A, Muranishi S (1997) Calcein is excreted from the intestinal mucosal cell membrane by the active transport system. Life Sci 60:307–313

Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH (2004) Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311:476–484

Koga T, Fukuda K, Shimada Y, Fukami M, Koike H, Tsujita Y (1992) Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209:315–319

Horikawa M, Kato Y, Tyson CA, Sugiyama Y (2002) The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metabol Pharmacokin 17:23–33